Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial

Beatriz Grinsztejn, Jean‐Michel Molina, Vincent Arnold et al.|The Lancet Infectious Diseases|2014

Cited by 98